Biomarker analysis of Morquio syndrome: identification of disease state and drug responsive markers

Table 7 Longitudinal presentation of analyte data post-ERT (baseline, 12, 24, and 36 weeks).

Comparisons versus baseline
	Week 12 (p < 0.01)*	Week 24 (p < 0.01)	Week 36 (p < 0.001)
Increased over baseline	Apoliprotein CIII	Alpha-1-antitrypsin	Alpha-1-antitrypsin
	MCP-1	Apolipoprotein CIII	Apolipoprotein CIII
	MMP-2	Complement 3	Complement 3
	Thrombopoietin	Endothelin-1	MMP-2
		Fibrinogen	IgM
		MCP-1	Fibrinogen
		MIP-1 alpha
		MMP-2
Decreased over baseline	Alpha-2 macroglobulin	IL-4	CD40
	SGOT	IL-13	SGOT
	VCAM-1	IL-1 alpha	Apoliprotein A1
		SGOT
		VCAM-1
Comparison between treatment weeks
	Week 12 vs. 24 (p < 0.05)	Week 12 vs. 36 (p < 0.01)	Week 24 vs. 36 (p < 0.05)
Increased over time	Alpha-1-antitrypsin	Alpha-1-antitrypsin	Complement 3
	Apolipoprotein H	Apolipoprotein H
	Complement 3	Complement 3
	Endothelin-1	Endothelin-1
	IgM	IGF-1
	IgA	IgM
	MIP-1 alpha	Serum amyloid P
	Serum amyloid P	TNF-alpha
	von Willebrand Factor
Decreased over time	Alpha-fetoprotein	Apolipoprotein A1	CD40
	Fatty acid binding protein	CD40
	IL-3	IL-3
	IL-4
	IL-7
	IL-13
	Thrombopoietin

*T-tests were performed at a variety of different p-values including p < 0.05, p < 0.01, and p < 0.001. The significance level that gave the best separation between groups is reported.

ISSN: 1750-1172